

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1 (Currently Amended). A compound comprising a moiety having an iron chelator function, said iron chelating moiety being selected from the group consisting of an 8-hydroxyquinoline moiety, an hydroxamate moiety, and a pyridinone moiety, and, in addition, one or both of the following moieties: (i) a moiety ~~selected from the group consisting of a moiety that~~ imparts a neuroprotective function to the compound, said neuroprotective moiety being selected from the group consisting of an L- or D-cysteine or an L- or D-alanine residue, a neuroprotective peptide, a neuroprotective peptide fragment, and an analog of said neuroprotective peptide or neuroprotective peptide fragment; and (ii) a moiety that imparts combined antiapoptotic and neuroprotective function to the compound, said antiapoptotic and neuroprotective moiety being a propargyl grouper both.

2 (Currently Amended). A compound according to claim 1, wherein said antiapoptotic and neuroprotective moiety ~~imparting combined antiapoptotic and neuroprotective functions~~ is a ~~propargyl~~ propargylamine group.

3 (Cancelled).

4 (Currently Amended). A compound according to claim ~~31~~, ~~wherein the iron chelator function is a moiety of consisting of an 8-hydroxy-5-quinoline8-hydroxyquinoline, a 3-hydroxypyridin-4-one, or a 1-hydroxypyridin-2-one of the formulas:~~



wherein R represents the ~~group carrying the neuroprotective function and/or combined~~ moiety or the neuroprotective and antiapoptotic ~~functions~~ moiety, wherein R ~~that may be~~ is linked at position 5, 6 or 7 of the quinoline ring, at position 1, 2, 5 or 6 of the 3-hydroxy-4-pyridinone ring, wherein R' is C₁-C₄ lower alkyl, or at position 4 or 5 of the 1-hydroxy-2-pyridinone ring.

5 (Currently Amended). A compound according to claim 4, ~~consisting of said wherein the iron chelating function is provided by the 8-hydroxy-5-quinolinylmethylene group~~ 8-hydroxyquinoline.

6 (Withdrawn/Currently Amended). A compound according to claim 4, ~~consisting of said wherein the iron chelating function is provided by a 2-methyl-3-hydroxy-4-~~

~~pyridinone group~~ 3-hydroxypyridin-4-one, wherein R' is 2-
methyl.

7 (Withdrawn/Currently Amended). A compound
according to claim 1, wherein ~~the~~ said neuroprotective moiety
~~imparting a neuroprotective function to the compound is~~
selected from the group consisting of a neuroprotective
peptide, a neuroprotective peptide fragment, an analog of said
neuroprotective peptide, and an analog of said neuroprotective
peptide fragment ~~a neuroprotective analog and a neuroprotective~~
~~fragment thereof~~.

8 (Withdrawn/Currently Amended). A compound
according to claim 7, wherein said neuroprotective peptide is
vasoactive intestinal peptide (VIP), gonadotropin-releasing
hormone (GnRH), Substance P or enkephalin.

9 (Withdrawn/Currently Amended). A compound
according to claim ~~8~~ 7, wherein said neuroprotective peptide
analog is an analog of VIP, GnRH, Substance P or enkephalin or
of a fragment thereof, in which one amino acid residue is
replaced by ~~a~~ an L- or D-cysteine residue.

10 (Withdrawn/Currently Amended). A compound
according to claim 9, wherein said analog is selected from the
group consisting of an analog of the VIP fragment ~~analog~~ ~~s of~~
SEQ ID NO:2 that may bear a stearyl or a Fmoc group at the
amino terminal, the GnRH analogs of SEQ ID NO:4 and SEQ ID

NO:5, the Substance P analogs of SEQ ID NO:7 and SEQ ID NO:8, and the enkephalin analogs of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

11 (Withdrawn/Currently Amended). A compound according to claim 1, wherein the moiety imparting a neuroprotective function to the compound is ~~a~~an L- or D-cysteine or L- or D-alanine residue.

12 (Withdrawn/Currently Amended). A compound according to claim 1, comprising ~~a~~an 8-hydroxy-5-quinolinyl iron-chelating ~~function~~moiety and a residue of a neuroprotective peptide, a neuroprotective peptide fragment, an analog of said neuroprotective peptide, and an analog of said neuroprotective peptide fragment ~~a neuroprotective analog or a neuroprotective fragment thereof~~ as the neuroprotective ~~function~~moiety.

13 (Withdrawn/Currently Amended). A compound according to claim 12, wherein said neuroprotective ~~peptide moiety~~ is vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P or enkephalin.

14 (Withdrawn/Currently Amended). A compound according to claim ~~13~~12, wherein said neuroprotective ~~peptide moiety~~ is an analog of VIP, GnRH, Substance P or enkephalin, or of a fragment thereof in which one amino acid residue is replaced by ~~a~~an L- or D-cysteine residue.

15 (Withdrawn/Currently Amended). A compound according to claim 14, wherein said analog is selected from the group consisting of an analog of the VIP fragment ~~analog~~ of SEQ ID NO:2 that may bear a stearyl or a Fmoc group at the amino terminal, the GnRH analogs of SEQ ID NO:4 and SEQ ID NO:5, the Substance P analogs of SEQ ID NO:7 and SEQ ID NO:8, and the enkephalin analogs of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

16 (Withdrawn/Currently Amended). A compound according to claim 12, further comprising a propargyl group.

17 (Withdrawn/Currently Amended). A compound according to claim 1, comprising a 8-hydroxy-5-quinolinyl iron-chelating ~~function~~ moiety and a residue of L- or D-cysteine or L- or D-alanine.

18 (Withdrawn/Currently Amended). A compound according to claim 17, further comprising a propargyl group.

19 (Currently Amended). A compound according to claim 1, comprising a 8-hydroxy-5-quinolinyl iron-chelating ~~function~~ moiety and a propargyl group.

20 (Currently Amended). A compound according to claim 19, wherein said ~~8-hydroxy-5-quinolinyl is the iron~~ chelating moiety is an 8-hydroxy-5-quinolinylmethylene radical that is linked to the propargyl group via -N- atom(s).

21 (Withdrawn/Currently Amended). A compound according to claim 20, wherein said 8-hydroxy-5-quinolinylmethylene radical is linked to the propargyl group via a linker selected from the group consisting of ethylenediamine, piperazine and 1,3,5-perhydrotriazine moiety.

22 (Withdrawn/Currently Amended). A compound according to claim 21, wherein said 8-hydroxy-5-quinolinylmethylene radical is linked to the propargyl group via a piperazine moiety.

23 (Withdrawn/Currently Amended). A compound according to claim 20, wherein said 8-hydroxy-5-quinolinylmethylene radical is linked to the propargyl group via the -NH- group of ~~a~~ an L- or D-alanine or L- or D-cysteine residue or an ester thereof.

24 (Withdrawn/Currently Amended). A compound according to claim 1, comprising a hydroxamate iron-chelating ~~function moiety~~ and a residue of a neuroprotective peptide, a neuroprotective peptide fragment, an analog or a of said neuroprotective peptide, or an analog of said neuroprotective peptide fragment, thereof as the neuroprotective ~~function moiety~~.

25 (Withdrawn/Currently Amended). A compound according to claim 24, wherein said neuroprotective ~~peptide~~

moiety is vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P or enkephalin.

26 (Withdrawn/Currently Amended). A compound according to claim ~~25~~24, wherein said neuroprotective peptide analog is an analog of VIP, GnRH, Substance P or enkephalin, or of a fragment thereof in which one amino acid residue is replaced by ~~a~~an L- or D-cysteine residue.

27 (Withdrawn/Currently Amended). A compound according to claim 26, wherein said analog is selected from the group consisting of an analog of the VIP fragment ~~analog~~ of SEQ ID NO:2 that may bear a stearyl or a Fmoc group at the amino terminal, the GnRH analogs of SEQ ID NO:4 and SEQ ID NO:5, the Substance P analogs of SEQ ID NO:7 and SEQ ID NO:8, and the enkephalin analogs of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

28 (Withdrawn/Currently Amended) A compound according to claim 24, further comprising a propargyl group.

29 (Withdrawn/Currently Amended). A compound according to claim 1, comprising a N-ethylene-2-hydroxy-3-methyl-pyridin-4-one iron-chelating ~~function~~moiety, and a residue of a neuroprotective peptide, a neuroprotective peptide fragment, an analog of said neuroprotective peptide, or an analog of said neuroprotective peptide fragment, ~~thereof~~ as the neuroprotective ~~function~~moiety.

30 (Withdrawn/Currently Amended). A compound according to claim 29, wherein said neuroprotective ~~peptide moiety~~ is vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P or enkephalin.

31 (Withdrawn/Currently Amended). A compound according to claim ~~30~~-29, wherein said neuroprotective peptide analog is an analog of VIP, GnRH, Substance P or enkephalin, or of a fragment thereof in which one amino acid residue is replaced by ~~a~~-an L- or D-cysteine residue.

32 (Withdrawn/Currently Amended). A compound according to claim 31, wherein said analog is selected from the group consisting of an analog of the VIP fragment ~~analog~~s of SEQ ID NO:2 that may bear a stearyl or a Fmoc group at the amino terminal, the GnRH analogs of SEQ ID NO:4 and SEQ ID NO:5, the Substance P analogs of SEQ ID NO:7 and SEQ ID NO:8, and the enkephalin analogs of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

33 (Withdrawn/Currently Amended) A compound according to claim 29, further comprising a propargyl group.


34 (Withdrawn/Currently Amended). A compound according to claim 1, comprising a N-ethylene-2-hydroxy-3-methyl-pyridin-4-one iron-chelating ~~function~~moiety, a residue of L- or D-cysteine or L- or D-alanine and a propargyl group.

35 (Withdrawn/Currently Amended). A compound according to claim 1, comprising a hydroxamate iron-chelating ~~function moiety~~ and a propargyl group.


36 (Withdrawn/Currently Amended). A compound according to claim 35, wherein said hydroxamate is a CONHOH-(CH₂)₂- ~~radical moiety~~ that is linked to the propargyl group via -N- atom(s).

37 (Withdrawn/Currently Amended). A compound according to claim 35, wherein said hydroxamate ~~radical moiety~~ is linked to the propargyl group via a piperazine ring.


38 (Currently Amended). ~~A~~ The compound according to claim ~~3~~ 1 of the formula I to IV, or a pharmaceutically acceptable salt thereof:




I



II



III



IV


wherein:

R₁ is a residue of an analog of a neuroprotective peptide, or of a fragment thereof, containing a cysteine residue that is linked to the C atom via the -S- atom of the L- or D-Cys residue, and wherein the amino terminal of the


peptide is unsubstituted or substituted by a hydrophobic group;

R_2 is H or $-NH-X$;

R_3 is a group selected from the group consisting of



R_4 is a group selected from the group consisting of



R_5 is H, C_1-C_4 lower alkyl or $COOC_2H_5$;

R_6 is H, $COOH$, COO^- or $COOC_2H_5$;


R_7 is selected from the group consisting of $\text{(i)} -NH-R_8-NH-R'_8$; $\text{(ii)} -NH_3^+$; $\text{(iii)} -NH-COCH_3$; $\text{(iv)} -NH-NH-R_8$; and $\text{(v)} -NH-NH-CO-CH(CH_2OH)-NH-R_8$;



R_8 is H or $-X$;

R'_8 is H, X or Fmoc;

R_9 is selected from the group consisting of $\text{(i)} -H$;



$\text{(ii)} -CO-CH_2-R_1$; $\text{(iii)} -CH_2-COOC_2H_5$; $\text{(iv)} -CH(CH_2SH)COOC_2H_5$;





n is an integer from 1 to 6;

R₁₁ is a group selected from the group consisting of




R₁₂ is X, C₁-C₄ lower alkyl, preferably CH₃, COOC₂H₅ or ~~---(CH₂)₂OH---~~ ---(CH₂)₂OH;

R₁₃ is X, ~~---(CH₂)₂OX-~~, or ~~---COO-(CH₂)₂-NH-X~~; and

X is a propargyl group, ~~but excluding the compound~~
~~5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline~~
provided that when R₃ is -CR₅R₆R₇, R₆ is COOC₂H₅ and R₇
is -NH-R'₈, then R'₈ is X.

39 (Withdrawn/Currently Amended). ~~A~~ The compound
~~according to claim 38 of the formula I or a pharmaceutically~~
~~acceptable salt thereof~~ according to claim 38, of the formula
I:



I

wherein

R₁ is a residue of an analog of a neuroprotective peptide or of a fragment thereof containing a~~an~~ L- or D-cysteine residue that is linked to the C atom via the -S- atom of the Cys residue, and wherein the amino terminal of the peptide is unsubstituted or substituted by a hydrophobic group;

R₂ is H or -NH-X; and

X is a propargyl group.

40 (Withdrawn/Currently Amended). ~~A~~The compound of the formula I according to claim 39, wherein R₁ is an analog of a neuroprotective peptide, or of a fragment thereof, in which one amino acid residue has been replaced by an L- or D-cysteine residue, wherein said neuroprotective peptide is selected from the group consisting of vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P and enkephalin; ~~or a fragment thereof in which one amino acid residue has been replaced by a L- or D-cysteine residue~~ and R₂ is H.


41 (Withdrawn/Currently Amended). A compound according to claim 40, wherein said analog is selected from the group consisting of an analog of the VIP fragment ~~analog~~ of SEQ ID NO:2 bearing a stearyl (identified herein as compound M6, Appendix II) or a Fmoc group (M7, Appendix II) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (M8, Appendix II) or SEQ ID NO:5 (M22, Appendix II), the residue of a Substance P analog of SEQ ID NO:7 (M27, Appendix II) or SEQ ID NO:8 (M28, Appendix II), and the residue of an enkephalin analog of SEQ ID NO:11 (M19, Appendix II), SEQ ID NO:12 (M21, Appendix II), SEQ ID NO:13 (M18, Appendix II), and SEQ ID NO:14 (M20, Appendix II).

42 (Withdrawn/Currently Amended). A compound of the formula I according to claim 39, wherein R₁ is an analog of a neuroprotective peptide, or of a fragment thereof, in which one amino acid residue has been replaced by an L- or D-cysteine residue, said neuroprotective peptide being selected from the group consisting of vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P or enkephalin; ~~or a fragment thereof in which one amino acid residue has been replaced by a L- or D-cysteine residue~~ and R₂ is -NH-propargyl.

43 (Withdrawn/Currently Amended). A compound according to claim 42, wherein said analog is selected from

the group consisting of the residue of an analog of the VIP fragment ~~analog~~ of SEQ ID NO:2 bearing a stearyl (M6A, Appendix I) or a Fmoc group (M7A, Appendix I) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (M8A) or SEQ ID NO:5 (M22A, Appendix I), the residue of a Substance P analog of SEQ ID NO:7 (M27A, Appendix I) or SEQ ID NO:8 (M28A, Appendix I), and the residue of an enkephalin analog of SEQ ID NO:11 (M19A, Appendix I), SEQ ID NO:12 (M21A, Appendix I), SEQ ID NO:13 (M18A, Appendix I), and SEQ ID NO:14 (M20A, Appendix I).


44 (Currently Amended). ~~A~~ The compound according to claim 38, ~~of the formula II or a pharmaceutically acceptable salt thereof,~~ of the formula II:



II

wherein

R₃ is a group selected from the group consisting of



~~(ii)~~ $-\text{CR}_5\text{R}_6\text{R}_7$; ~~(iii)~~ $-\text{N}(\text{CH}_3)-\text{X}$; ~~(iv)~~ $-\text{N}(\text{R}_8)-\text{CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$;
~~(v)~~ $-\text{N}(\text{R}_8)-\text{CH}_2-\text{COOCH}_2\text{C}_6\text{H}_5$; and ~~(vi)~~ $-\text{S}-\text{CH}_2-\text{CH}(\text{COOH})-\text{NHR}_8-\text{NHR}'_8$;

R_4 is a group selected from the group consisting of

~~(i)~~ X ; ~~(ii)~~ COOC_2H_5 ; ~~(iii)~~ $(\text{CH}_2)_2-\text{O}-\text{R}_8$; and ~~(iv)~~ $-\text{COO}-(\text{CH}_2)_2-\text{NH}-$
 R_8 ;

R_5 is H, CH_3 or COOC_2H_5 ;

R_6 is H, COOH , COO^- or COOC_2H_5 ;

R_7 is selected from the group consisting of ~~(i)~~ $-\text{NH}-$
 $\text{R}_8-\text{NH}-\text{R}'_8$; ~~(ii)~~ $-\text{NH}_3^+$; ~~(iii)~~ $-\text{NH}-\text{COCH}_3$; ~~(iv)~~ $-\text{NH}-\text{NH}-\text{R}_8$; and
~~(v)~~ $-\text{NH}-\text{NH}-\text{CO}-\text{CH}(\text{CH}_2\text{OH})-\text{NH}-\text{R}_8$;

R_8 is ~~H~~ or X ;

R'_8 is H, X or Fmoc; and

X is a propargyl group, ~~but excluding the compound~~
~~5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline~~
provided that when R_3 is $-\text{CR}_5\text{R}_6\text{R}_7$, R_6 is COOC_2H_5 and R_7
is $-\text{NH}-\text{R}'_8$, then R'_8 is X.

45 (Withdrawn/Currently Amended). A compound of
formula II according to claim 44, wherein R_3 is a piperazine
ring, ~~but excluding the compound wherein R_4 is $-(\text{CH}_2)_2-\text{OH}$.~~

46 (Cancelled).

47 (Withdrawn/Currently Amended). A compound of
formula II according to claim 44, wherein R_3 is a piperazine
ring and R_4 is a propargyl group, as represented by the
compound herein designated HLA20 (Appendix III).

48 (Withdrawn/Currently Amended). A compound of formula II according to claim 44, wherein R_3 is a piperazine ring as represented by the compounds herein designated HLA16a and M17 (Appendix III).

49 (Withdrawn/Currently Amended). A compound of formula II according to claim 44, wherein R_3 is $-S-CH_2-CH(COOH)-\underline{NHR'_8}-\underline{NHR'_8}$ and $R_8-R'_8$ is H, as represented by the compounds herein designated D-HQ-CysOH (M11, Appendix II) and L-HQ-CysOH (M12, Appendix II), or $R_8-R'_8$ is propargyl, as represented by the compounds herein designated D-(HQ-Pr)-CysOH (M11a, Appendix III) and L-(HQ-Pr)-CysOH (M12a, Appendix III), or $R_8-R'_8$ is Fmoc, as represented by the compounds herein designated M11B and M12B (Appendix IV).


50 (Withdrawn/Currently Amended). A compound of formula II according to claim 44, wherein R_3 is a group $-CR_5R_6R_7$, wherein R_5 is H, R_6 is COOH, R_7 is $-\underline{NH-R_8}-\underline{NH-R'_8}$ and $R_8-R'_8$ is H, as represented by the compounds herein designated D-HQ-Ala (M9, Appendix IV) and L-HQ-Ala (M10, Appendix IV); or $R_8-R'_8$ is propargyl, as represented by the compounds herein designated D-(HQ-Pr)-Ala (M9a, Appendix III) and L-(HQ-Pr)-Ala (M10a, Appendix III); or R_5 is H, R_6 is COO^- and R_7 is $-NH_2^+$, as represented by the compound herein designated HQ-Ala (HLM8, Appendix IV); or R_5 is H, R_6 is $COOC_2H_5$ and R_7 is $-NH_2$, as represented by the compound herein designated HQ-AlaEt (HLM9,

~~Appendix IV); or R₅ and R₆ are both COOC₂H₅, and R₇ is -NH-~~
~~COCH₃, as represented by the compound herein designated HLM7~~
~~(Appendix IV); or R₅ is H, R₆ is COOC₂H₅ and R₇ is -NH-~~
propargyl, as represented by the compound herein designated
M31 (Appendix III).

51 (Withdrawn/Currently Amended). A compound of
formula II according to claim 44, wherein R₃ is a group -NR₈-
CH(CH₂SH)COOC₂H₅, wherein ~~R₈ is H, as represented by the~~
~~compound herein designated M32 (Appendix IV); or R₈ is~~
propargyl, as represented by the compound herein designated
M33 (Appendix III).

52 (Currently Amended). A compound of formula II
according to claim 44, wherein R₃ is a group -N(CH₃)-propargyl,
as represented by the compound herein designated M30 (Appendix
III).



53 (Withdrawn/Currently Amended). A compound
according to claim 38, ~~of formula III~~ or a pharmaceutically
acceptable salt thereof, of the formula III:





III

wherein

R_9 is selected from the group consisting of ~~(i)~~-H;
~~(ii)~~-CO-CH₂-R₁; ~~(iii)~~-CH₂-COOCH₂C₆H₅; ~~(iv)~~-CH(CH₂SH)COOC₂H₅;

~~(v)~~-CO-CH₂-N  N-R₁₂ ; ~~(vi)~~ -CO-CH₂-  -OH; and

~~(vii)~~ -CO-CH₂-  ;

R_{10} is X; ~~-CH(CH₂SH)COOC₂H₅~~ or  ;

n is an integer from 1 to 6;

R_{12} is X, C₁-C₄ lower alkyl, COOC₂H₅, or -(CH₂)₂-OH;

and

X is a propargyl group.


54 (Withdrawn/Currently Amended). A compound of formula III according to claim 53, wherein R_9 is -CO-CH₂-R₁, wherein R₁ is the residue of an analog of a neuroprotective peptide or of a fragment thereof containing a L- or D-Cys residue.

55 (Withdrawn/Currently Amended). A compound of formula III according to claim 54, wherein said analog is selected from the group consisting of the residue of an analog of a VIP fragment ~~analog~~ of SEQ ID NO:2 bearing a stearyl (M6B, Appendix V) or a Fmoc group (M7B, Appendix V) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4

(M8B, Appendix V) or SEQ ID NO:5 (M22B, Appendix V), the residue of a Substance P analog of SEQ ID NO:7 (M27B, Appendix V) or SEQ ID NO:8 (M28B, Appendix V), and the residue of an enkephalin analog of SEQ ID NO:11 (M19B, Appendix V), SEQ ID NO:12 (M21B, Appendix V), SEQ ID NO:13 (M18B, Appendix V), and SEQ ID NO:14 (M20B, Appendix V).

56 (Withdrawn/Currently Amended). A compound of formula III according to claim 53, as represented by the compounds herein designated M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45 and M46 (Appendix V).

57 (Withdrawn/Currently Amended). A compound according to claim 38, ~~of formula IV~~ or a pharmaceutically acceptable salt thereof, of the formula IV:




IV

wherein

R₁₁ is selected from the group consisting of

~~(i)~~ -S-CH₂-CH(COOH)-NH-X; ~~(ii)~~ -N(X)-CH₂COO-CH₂-C₆H₅; ~~(iii)~~ -N(CH₃)-X; ~~(iv)~~ -N(X)-CH(CH₂SH)COOC₂H₅; ~~(v)~~ -CH₂-NH-NH-CO-CH(CH₂OH)-NH-X; ~~(vi)~~ -C(CH₃)(COOH)-NH-NH-X; ~~(vii)~~ -CH(COOH)-NH-X; ~~(viii)~~ -CH(COOC₂H₅)-NH-X; CH(COOC₂H₅)-NH-X; and



R₁₃ is X, -(CH₂)₂-OX, or -COO-(CH₂)₂-NH-X; and

X is a propargyl group.

58 (Withdrawn/Currently Amended). A compound of formula IV according to claim 57, as represented by the compounds herein designated M9b, M11b, M12b, M13b, M15b, HLA16b, M17a, HLA20a, M30a, M31a, M33a, and M34b (Appendix VI).

59 (Currently Amended). A compound of formula I, II, III or IV according to claim 38, as depicted in the Appendices I to VI herein, but excluding the compound designated VK-28 in Appendix IV.

60 (Currently Amended). A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claims 61- 79 (Cancelled).

80 (Withdrawn/Currently Amended). ~~The~~ A method ~~according to claim 79~~ for treatment and/or prevention of a disease, disorder or condition associated with iron overload, and oxidative stress and neurodegeneration, which comprises administering to an individual in need thereof an effective amount of a compound of claim 1.

81 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for the prevention and/or treatment of a neurodegenerative disease, condition or disorder.

82 (Cancelled).

83 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for the prevention and/or treatment of iron overload in hemochromatosis or thalassemia patients.

84 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for prevention and/or treatment of a cardiovascular disease.

85 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for prevention and/or treatment of diabetes.

86 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for prevention and/or treatment of an inflammatory disorder.

87 (Withdrawn/Currently Amended). The method according to claim ~~86~~87, wherein the inflammatory disorder is a joint inflammatory disorder, particularly rheumatoid arthritis, inflammatory bowel disease (IBD) or psoriasis.

88 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for prevention and/or treatment of anthracycline cardiotoxicity in an individual undergoing treatment with anthracycline neoplastic drugs.

89 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for prevention and/or treatment of a viral, protozoal or yeast infection.

90 (Withdrawn/Currently Amended). The method according to claim 89, wherein said viral infection is a retroviral infection.

91 (Withdrawn/Currently Amended). The method according to claim 89, wherein said protozoal infection is malaria caused by *Plasmodium falciparum*, and said yeast infection is a *Candida albicans* infection.

92 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for retarding ageing and/or improving the ageing process in a healthy individual or an individual suffering from an age-related disease.

93 (Withdrawn/Currently Amended). The method according to claim 79 for prevention and/or treatment of skin ageing and/or skin damage associated with ageing.

94 (Withdrawn/Currently Amended). The method according to claim ~~79~~80, for prevention and/or treatment of skin damage associated with exposure to sunlight and/or UV light.

95-98 (Cancelled).

99 (Withdrawn/Currently Amended). A compound according to claim 13, further comprising a propargyl group.

100 (Withdrawn/Currently Amended). A compound
| according to claim 14, further comprising a propargyl group.

101 (Withdrawn/Currently Amended). A compound
| according to claim 15, further comprising a propargyl group.

102 (Withdrawn/Currently Amended). A compound
| according to claim 25, further comprising a propargyl group.

103 (Withdrawn/Currently Amended). A compound
| according to claim 26, further comprising a propargyl group.

104 (Withdrawn/Currently Amended). A compound
| according to claim 27, further comprising a propargyl group.

105 (Withdrawn/Currently Amended). A compound
| according to claim 30, further comprising a propargyl group.

106 (Withdrawn/Currently Amended). A compound
| according to claim 31, further comprising a propargyl group.

107 (Withdrawn/Currently Amended). A compound
| according to claim 32, further comprising a propargyl group.

108 (Withdrawn/Currently Amended). A compound
| according to claim 36, wherein said hydroxamate radical is
| linked to the propargyl group via a piperazine ring.

109 (Currently Amended). A pharmaceutical
| composition comprising a compound according to claim 38, or a
| pharmaceutically acceptable salt thereof, and a
| pharmaceutically acceptable carrier.

110 (Cancelled).

111 (Withdrawn/Currently Amended). ~~The~~ A method according to claim ~~110~~ for treatment and/or prevention of a disease, disorder or condition associated with iron overload, and oxidative stress and neurodegeneration, which comprises administering to an individual in need thereof an effective amount of a compound of claim 38.

112 (Withdrawn/Currently Amended). The method according to claim ~~110~~ 111, for the prevention and/or treatment of a neurodegenerative disease, condition or disorder.

113 (Cancelled).

114 (Withdrawn/Currently Amended). The method according to claim ~~110~~ 111, for the prevention and/or treatment of iron overload in hemochromatosis or thalassemia patients.

115 (Withdrawn/Currently Amended). The method according to claim ~~110~~ 111, for prevention and/or treatment of a cardiovascular disease.

116 (Withdrawn/Currently Amended). The method according to claim 115, for prevention of damage associated with free radical generation in reperfusion injury.

117 (Withdrawn/Currently Amended). The method according to claim 84, for prevention of damage associated with free radical generation in reperfusion injury.

118 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for prevention and/or treatment of diabetes.

119 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for prevention and/or treatment of an inflammatory disorder.

120 (Withdrawn/Currently Amended). The method according to claim 119, wherein the inflammatory disorder is a joint inflammatory disorder, particularly rheumatoid arthritis, inflammatory bowel disease (IBD) or psoriasis.

121 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for prevention and/or treatment of anthracycline cardiotoxicity in an individual undergoing treatment with anthracycline neoplastic drugs.

122 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for prevention and/or treatment of a viral, protozoal or yeast infection.

123 (Withdrawn/Currently Amended). The method according to claim 122, wherein said viral infection is HIV-1, and the compound is administered to an AIDS patient, optionally in combination with antiviral agents.

124 (Withdrawn/Currently Amended). The method according to claim 122, wherein said protozoal infection is

malaria caused by *Plasmodium falciparum*, and said yeast infection is a *Candida albicans* infection.

125 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for retarding ageing and/or improving the ageing process in a healthy individual or an individual suffering from an age-related disease.

126 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for prevention and/or treatment of skin ageing and/or skin damage associated with ageing.

127 (Withdrawn/Currently Amended). The method according to claim ~~110~~-111, for prevention and/or treatment of skin damage associated with exposure to sunlight and/or UV light.

128 (Withdrawn/Currently Amended). The method according to claim 90, wherein said viral infection is HIV-1, and the compound is administered to an AIDS patient, optionally in combination with antiviral agents.

129-130 (Cancelled).

131 (Withdrawn/Currently Amended). The method according to claim ~~129~~84, wherein said cerebrovascular disorder is stroke.

132 (Withdrawn). A method for the prevention and/or treatment of a neurodegenerative or cerebrovascular disease, condition or disorder, which comprises administering to an

individual in need thereof an effective amount of a compound of claim 38.

133-135 (Cancelled).

136 (Withdrawn). A method for treatment of skin damage associated with ageing and/or exposure to sunlight and/or UV light which comprises administering to an individual in need thereof an effective amount of a compound of claim 38.

137 (Cancelled).

138 (Withdrawn). A method for preservation of an organ intended for transplantation which comprises treating said organ ex-vivo with an effective amount of a compound of claim 38.

139-140 (Cancelled).